首页> 外文期刊>Canadian Urological Association Journal >Circulating tumour cells in patients with urothelial tumours: Enrichment and in vitro culture
【24h】

Circulating tumour cells in patients with urothelial tumours: Enrichment and in vitro culture

机译:尿路上皮肿瘤患者的循环肿瘤细胞:富集和体外培养

获取原文
           

摘要

Introduction: Results of clinical trials have demonstrated that circulating tumour cells (CTCs) are frequently detected in patients with urothelial tumours. The monitoring of CTCs has the potential to improve therapeutic management at an early stage and also to identify patients with increased risk of tumour progression or recurrence before the onset of clinically detected metastasis. In this study, we report a new effectively simplified methodology for a separation and in vitro culturing of viable CTCs from peripheral blood. Method: We include patients diagnosed with 3 types of urothelial tumours (prostate cancer, urinary bladder cancer, and kidney cancer). A size-based separation method for viable CTC - enrichment from unclothed peripheral blood has been introduced (MetaCell, Ostrava, Czech Republic). The enriched CTCs fraction was cultured directly on the separation membrane, or transferred from the membrane and cultured on any plastic surface or a microscopic slide. Results: We report a successful application of a CTCs isolation procedure in patients with urothelial cancers. The CTCs captured on the membrane are enriched with a remarkable proliferation potential. This has enabled us to set up in vitro cell cultures from the viable CTCs unaffected by any fixation buffers, antibodies or lysing solutions. Next, the CTCs were cultured in vitro for a minimum of 10 to 14 days to enable further downstream analysis (e.g., immunohistochemistry). Conclusion: We demonstrated an efficient CTCs capture platform, based on a cell size separation principle. Furthermore, we report an ability to culture the enriched cells – a critical requirement for post-isolation cellular analysis.
机译:简介:临床试验结果表明,尿路上皮肿瘤患者经常检测到循环肿瘤细胞(CTC)。 CTC的监测具有在早期改善治疗管理的潜力,并且还可以在临床检测到的转移发生之前识别出肿瘤进展或复发风险增加的患者。在这项研究中,我们报告了一种新的有效简化的方法,用于从外周血中分离和体外培养可行的四氯化碳。方法:我们包括被诊断患有三种类型的尿路上皮肿瘤(前列腺癌,膀胱癌和肾癌)的患者。引入了一种基于大小的可行的四氯化碳分离方法-从裸露的外周血中富集(捷克共和国俄斯特拉发MetaCell)。富集的CTC馏分直接在分离膜上培养,或从膜上转移并在任何塑料表面或显微镜载玻片上培养。结果:我们报告了CTC分离程序在尿路上皮癌患者中的成功应用。捕获在膜上的四氯化碳富含显着的增殖潜力。这使我们能够从活的四氯化碳建立体外细胞培养物,而不受任何固定缓冲液,抗体或裂解溶液的影响。接下来,将CTC在体外培养至少10到14天,以便进行进一步的下游分析(例如免疫组织化学)。结论:我们展示了一种基于细胞大小分离原理的高效CTC捕获平台。此外,我们报告了培养富集细胞的能力-分离后细胞分析的关键要求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号